A ferrous-triapine complex mediates formation of reactive oxygen species that inactivate human ribonucleotide reductase

Jimin Shao, Bingsen Zhou, Angel J. Di Bilio, Lijun Zhu, Tieli Wang, Christina Qi, Jennifer Shih, Yun Yen

Research output: Contribution to journalArticle

105 Citations (Scopus)

Abstract

Ribonucleotide reductase plays a central role in cell proliferation by supplying deoxyribonucleotide precursors for DNA synthesis and repair. The holoenzyme is a protein tetramer that features two large (hRRM1) and two small (hRRM2 or p53R2) subunits. The small subunit contains a di-iron cluster/tyrosyl radical cofactor that is essential for enzyme activity. Triapine (3-aminopyridine-2-carboxaldehyde thiosemicarbazone, 3-AP) is a new, potent ribonucleotide reductase inhibitor currently in phase II clinical trials for cancer chemotherapy. Ferric chloride readily reacts with Triapine to form an Fe(III)-(3-AP) complex, which is reduced to Fe(II)-(3-AP) by DTT. Spin-trapping experiments with 5,5-dimethyl-1-pyrroline-N-oxide prove that Fe(II)-(3-AP) reduces O2 to give oxygen reactive species (ROS). In vitro activity assays show that Fe(II)-(3-AP) is a much more potent inhibitor of hRRM2 /hRRM1 and p53R2/hRRM1 than Triapine. Electron paramagnetic resonance measurements on frozen solutions of hRRM2 and p53R2 show that their tyrosyl radicals are completely quenched by incubation with Fe(II)-(3-AP). However, the enzyme activity is maintained in protein samples supplemented with catalase alone or in combination with superoxide dismutase. Furthermore, catalase alone or in combination with superoxide dismutase markedly decreases the antiproliferative effect of Triapine in cytotoxicity assays. These results indicate that Triapine-induced inhibition of ribonucleotide reductase is caused by ROS. We suggest that ROS may ultimately be responsible for the pharmacologic effects of Triapine in vivo.

Original languageEnglish
Pages (from-to)586-592
Number of pages7
JournalMolecular Cancer Therapeutics
Volume5
Issue number3
DOIs
Publication statusPublished - Mar 1 2006
Externally publishedYes

Fingerprint

Ribonucleotide Reductases
Reactive Oxygen Species
Catalase
Superoxide Dismutase
3-aminopyridine-2-carboxaldehyde thiosemicarbazone
Deoxyribonucleotides
Spin Trapping
Phase II Clinical Trials
Holoenzymes
Electron Spin Resonance Spectroscopy
Enzymes
DNA Repair
Proteins

ASJC Scopus subject areas

  • Oncology
  • Drug Discovery
  • Pharmacology

Cite this

A ferrous-triapine complex mediates formation of reactive oxygen species that inactivate human ribonucleotide reductase. / Shao, Jimin; Zhou, Bingsen; Di Bilio, Angel J.; Zhu, Lijun; Wang, Tieli; Qi, Christina; Shih, Jennifer; Yen, Yun.

In: Molecular Cancer Therapeutics, Vol. 5, No. 3, 01.03.2006, p. 586-592.

Research output: Contribution to journalArticle

Shao, Jimin ; Zhou, Bingsen ; Di Bilio, Angel J. ; Zhu, Lijun ; Wang, Tieli ; Qi, Christina ; Shih, Jennifer ; Yen, Yun. / A ferrous-triapine complex mediates formation of reactive oxygen species that inactivate human ribonucleotide reductase. In: Molecular Cancer Therapeutics. 2006 ; Vol. 5, No. 3. pp. 586-592.
@article{8cdea26be31e45168a2abf4fc3016d86,
title = "A ferrous-triapine complex mediates formation of reactive oxygen species that inactivate human ribonucleotide reductase",
abstract = "Ribonucleotide reductase plays a central role in cell proliferation by supplying deoxyribonucleotide precursors for DNA synthesis and repair. The holoenzyme is a protein tetramer that features two large (hRRM1) and two small (hRRM2 or p53R2) subunits. The small subunit contains a di-iron cluster/tyrosyl radical cofactor that is essential for enzyme activity. Triapine (3-aminopyridine-2-carboxaldehyde thiosemicarbazone, 3-AP) is a new, potent ribonucleotide reductase inhibitor currently in phase II clinical trials for cancer chemotherapy. Ferric chloride readily reacts with Triapine to form an Fe(III)-(3-AP) complex, which is reduced to Fe(II)-(3-AP) by DTT. Spin-trapping experiments with 5,5-dimethyl-1-pyrroline-N-oxide prove that Fe(II)-(3-AP) reduces O2 to give oxygen reactive species (ROS). In vitro activity assays show that Fe(II)-(3-AP) is a much more potent inhibitor of hRRM2 /hRRM1 and p53R2/hRRM1 than Triapine. Electron paramagnetic resonance measurements on frozen solutions of hRRM2 and p53R2 show that their tyrosyl radicals are completely quenched by incubation with Fe(II)-(3-AP). However, the enzyme activity is maintained in protein samples supplemented with catalase alone or in combination with superoxide dismutase. Furthermore, catalase alone or in combination with superoxide dismutase markedly decreases the antiproliferative effect of Triapine in cytotoxicity assays. These results indicate that Triapine-induced inhibition of ribonucleotide reductase is caused by ROS. We suggest that ROS may ultimately be responsible for the pharmacologic effects of Triapine in vivo.",
author = "Jimin Shao and Bingsen Zhou and {Di Bilio}, {Angel J.} and Lijun Zhu and Tieli Wang and Christina Qi and Jennifer Shih and Yun Yen",
year = "2006",
month = "3",
day = "1",
doi = "10.1158/1535-7163.MCT-05-0384",
language = "English",
volume = "5",
pages = "586--592",
journal = "Molecular Cancer Therapeutics",
issn = "1535-7163",
publisher = "American Association for Cancer Research Inc.",
number = "3",

}

TY - JOUR

T1 - A ferrous-triapine complex mediates formation of reactive oxygen species that inactivate human ribonucleotide reductase

AU - Shao, Jimin

AU - Zhou, Bingsen

AU - Di Bilio, Angel J.

AU - Zhu, Lijun

AU - Wang, Tieli

AU - Qi, Christina

AU - Shih, Jennifer

AU - Yen, Yun

PY - 2006/3/1

Y1 - 2006/3/1

N2 - Ribonucleotide reductase plays a central role in cell proliferation by supplying deoxyribonucleotide precursors for DNA synthesis and repair. The holoenzyme is a protein tetramer that features two large (hRRM1) and two small (hRRM2 or p53R2) subunits. The small subunit contains a di-iron cluster/tyrosyl radical cofactor that is essential for enzyme activity. Triapine (3-aminopyridine-2-carboxaldehyde thiosemicarbazone, 3-AP) is a new, potent ribonucleotide reductase inhibitor currently in phase II clinical trials for cancer chemotherapy. Ferric chloride readily reacts with Triapine to form an Fe(III)-(3-AP) complex, which is reduced to Fe(II)-(3-AP) by DTT. Spin-trapping experiments with 5,5-dimethyl-1-pyrroline-N-oxide prove that Fe(II)-(3-AP) reduces O2 to give oxygen reactive species (ROS). In vitro activity assays show that Fe(II)-(3-AP) is a much more potent inhibitor of hRRM2 /hRRM1 and p53R2/hRRM1 than Triapine. Electron paramagnetic resonance measurements on frozen solutions of hRRM2 and p53R2 show that their tyrosyl radicals are completely quenched by incubation with Fe(II)-(3-AP). However, the enzyme activity is maintained in protein samples supplemented with catalase alone or in combination with superoxide dismutase. Furthermore, catalase alone or in combination with superoxide dismutase markedly decreases the antiproliferative effect of Triapine in cytotoxicity assays. These results indicate that Triapine-induced inhibition of ribonucleotide reductase is caused by ROS. We suggest that ROS may ultimately be responsible for the pharmacologic effects of Triapine in vivo.

AB - Ribonucleotide reductase plays a central role in cell proliferation by supplying deoxyribonucleotide precursors for DNA synthesis and repair. The holoenzyme is a protein tetramer that features two large (hRRM1) and two small (hRRM2 or p53R2) subunits. The small subunit contains a di-iron cluster/tyrosyl radical cofactor that is essential for enzyme activity. Triapine (3-aminopyridine-2-carboxaldehyde thiosemicarbazone, 3-AP) is a new, potent ribonucleotide reductase inhibitor currently in phase II clinical trials for cancer chemotherapy. Ferric chloride readily reacts with Triapine to form an Fe(III)-(3-AP) complex, which is reduced to Fe(II)-(3-AP) by DTT. Spin-trapping experiments with 5,5-dimethyl-1-pyrroline-N-oxide prove that Fe(II)-(3-AP) reduces O2 to give oxygen reactive species (ROS). In vitro activity assays show that Fe(II)-(3-AP) is a much more potent inhibitor of hRRM2 /hRRM1 and p53R2/hRRM1 than Triapine. Electron paramagnetic resonance measurements on frozen solutions of hRRM2 and p53R2 show that their tyrosyl radicals are completely quenched by incubation with Fe(II)-(3-AP). However, the enzyme activity is maintained in protein samples supplemented with catalase alone or in combination with superoxide dismutase. Furthermore, catalase alone or in combination with superoxide dismutase markedly decreases the antiproliferative effect of Triapine in cytotoxicity assays. These results indicate that Triapine-induced inhibition of ribonucleotide reductase is caused by ROS. We suggest that ROS may ultimately be responsible for the pharmacologic effects of Triapine in vivo.

UR - http://www.scopus.com/inward/record.url?scp=33645473324&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645473324&partnerID=8YFLogxK

U2 - 10.1158/1535-7163.MCT-05-0384

DO - 10.1158/1535-7163.MCT-05-0384

M3 - Article

VL - 5

SP - 586

EP - 592

JO - Molecular Cancer Therapeutics

JF - Molecular Cancer Therapeutics

SN - 1535-7163

IS - 3

ER -